FDA to Review Safety Studies for Yaz and Yasmin

 

Yesterday, the Food and Drug Administration (FDA) announced it will be reviewing the findings of several Yaz and Yasmin studies that have been published recently. Many of these studies indicate that these popular birth control medications may lead to an increased risk of blood clots.

Currently, there is no talk of a recall for Yaz and Yasmin. However, many of the studies evaluating these drugs indicate that women should exercise caution when choosing whether to take them. Last month, the European Medicines Agency determined that Yaz, Yasmin, and all other birth control medications containing drospirenone are associated with a higher risk of venous thromboembolism. The agency recommended an update to the warning labels on these drugs that reflects this risk.

Two other studies published last month in the British Medical Journal also pointed out serious risks associated with Yaz and Yasmin. In particular, these studies found a 2-3 times greater risk of serious blood clots among women taking these birth control medications.

Bayer Healthcare, the manufacturer of Yaz and Yasmin, is currently facing several pharmaceutical injury lawsuits over these birth control products. The most high profile of these cases involves an 18-year-old college student who died last September of cardiac arrest after taking Yaz.

If you have suffered an injury from your use of Yaz or Yasmin, you might be entitled to receive compensation for your damages. It is important to work with an experienced drug injury lawyer who has the skills and resources to battle the high powered legal teams employed by pharmaceutical companies.